Sign Up
    OverviewAPI
    Biocytogen Pharmaceuticals has signed a collaboration agreement with Neurocrine Biosciences for the evaluation and option of fully human antibodies against specific targets. The agreement grants Neurocrine Biosciences access to Biocytogen's fully human antibodies and the right to license selected options for development, manufacturing, and global commercialization. The antibodies were generated using Biocytogen's RenMice® platform, aiming to accelerate the development of treatments for difficult-to-treat neurological diseases.

    Ask a question